BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37045981)

  • 1. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
    Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 4. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
    Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
    Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 8. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
    Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
    J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
    Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
    BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based analysis of different clinically significant prostate cancer detection rate of prostate imaging reporting and data system score 4 in the peripheral zone.
    Sun Z; Wang H; Fu W; Zhu S; Song G
    Abdom Radiol (NY); 2023 Jan; 48(1):390-398. PubMed ID: 36305943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of dynamic contrast enhancement on diffusion weighted imaging score of 3 in prostate imaging reporting and data system version 2 of peripheral zone].
    Wang W; Shao ZH; Huang XH; Xu Y; Feng X; Wang PJ
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):1002-1006. PubMed ID: 32294857
    [No Abstract]   [Full Text] [Related]  

  • 16. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
    Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
    Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer.
    Wang B; Gao J; Zhang Q; Zhang C; Liu G; Wei W; Huang H; Fu Y; Li D; Zhang B; Guo H
    Abdom Radiol (NY); 2020 Feb; 45(2):547-555. PubMed ID: 31907568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI.
    Nguyen TA; Fourcade A; Zambon A; Saout K; Deruelle C; Joulin V; Tissot V; Doucet L; Rozet F; Fournier G; Valeri A
    Urol Oncol; 2023 Aug; 41(8):354.e11-354.e18. PubMed ID: 37391283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
    Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
    Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.